Business Context and Reporting Period
Company: InflaRx N.V.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: August 9, 2018
Reporting Period: The filing incorporates by reference Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three and six months ended June 30, 2018.
Key Financial Metrics
The provided text is a cover sheet and exhibit index for Form 6-K. It does not contain the actual financial data. Specific values for revenue, profit, cash flow, margins, debt, and liquidity are located in Exhibit 99.1 (Financial Statements) and Exhibit 99.2 (MD&A), which are referenced but not included in the input text. Therefore, no numerical financial metrics can be extracted from this document alone.
Material Changes
The filing text does not provide specific details regarding material changes in financial performance or operations compared to prior periods. Such analysis is contained within the referenced Exhibit 99.2.
Guidance, Outlook, and Risks
Management Commentary: The filing references a Press Release dated August 9, 2018 (Exhibit 99.3), which likely contains management commentary, but the content of the release is not included in the text.
Risks and Contingencies: No specific risks or contingencies are detailed in the cover sheet. These are typically addressed in the MD&A (Exhibit 99.2) or the Press Release (Exhibit 99.3).
Unusual Items: The text does not disclose any unusual items.
Investor Verification Checklist
- Review Exhibit 99.1 for the actual Unaudited Condensed Consolidated Financial Statements to verify cash burn, liquidity, and operating expenses for the six months ended June 30, 2018.
- Examine Exhibit 99.2 (MD&A) for management's explanation of financial results and material changes from the prior period.
- Read Exhibit 99.3 (Press Release) for any updates on clinical trial progress, regulatory milestones, or strategic partnerships.
- Confirm the status of the registration statements on Form F-1 (No. 333-224596) and Form S-8 (No. 333-221656) into which these exhibits are incorporated.